期刊
JOURNAL OF MOLECULAR NEUROSCIENCE
卷 33, 期 1, 页码 105-113出版社
HUMANA PRESS INC
DOI: 10.1007/s12031-007-0041-4
关键词
adrenoleukodystrophy; therapy; Lorenzo's oil; glyceryl trioleate; glyceryl trierucate; fatty acids; erucic acid; very long chain fatty acids; clinical trials; newborn screening
X-linked adrenoleukodystrophy (X-ALD) is a genetic disorder that damages the nervous system and is associated with the accumulation of saturated very long chain fatty acids (SVLCFA). Oral administration of Lorenzo's oil (LO), a 4:1 mixture of glyceryl trioleate and glyceryl trierucate, normalizes the SVLCFA levels in plasma, but its clinical efficacy and the clinical indications for its use have been controversial for more than 15 years. We review the biochemical effects of LO administration and the rationale for its use and present a current appraisal of its capacity to reduce the risk for the childhood cerebral phenotype when administered to asymptomatic boys and to slow progression of adrenomyeloneuropathy in patients without cerebral involvement. We also present current efforts to provide definitive evaluation of its clinical efficacy and discuss its possible role in the new therapeutic opportunities that will arise if newborn screening for X-ALD is validated and implemented.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据